|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on June 21, 2002; DOI 10.1182/blood-2002-02-0643.
IMMUNOBIOLOGY
From the Institut National de la Santé et de la
Recherche Médicale (INSERM) U487 and Unité des
Thérapies innovantes, Institut Gustave Roussy, and Institut Andre
Lwoff-CNRS, Hôpital Paul Brousse, Villejuif, France; and
Unité d'Immunologie Moléculaire, Institut Pasteur, Paris,
France.
Renal cell carcinoma (RCC) infiltrating lymphocytes (TILs) express
killer cell immunoglobulinlike receptors (KIRs) that inhibit the
antitumor CD8+ T-cell lysis. In the present study, to
better examine the functional consequences of KIR engagement on
cytotoxic T lymphocyte (CTL)/tumor interaction, we have
investigated the influence of KIR CD158a on early steps of T-cell
activation. We show that coengagement of T-cell receptor (TCR)
and CD158a by tumor cells inhibited tyrosine phosphorylation of early
signaling proteins ZAP-70 and LAT, lipid raft coalescence, and TCR/CD3
accumulation at the CTL/tumor cell interface. In addition, the guanine
exchange factor Vav was not phosphorylated, and no actin cytoskeleton
rearrangement was observed. Our data indicate a role of KIR CD158a in
the dynamic events induced by TCR triggering, preventing CTL membrane
reorganization, and subsequent completion of CTL activation program.
Accordingly, the expression of CD158 by TILs may favor tumor cell
escape to the immune response.
(Blood. 2002;100:2874-2881) In humans, inhibitory natural killer (NK) receptors
for HLA-I molecules include killer cell immunoglobulinlike receptors
(KIRs), the CD94/NKG2A heterodimer, and immunoglobulinlike transcript 2 (ILT-2)/leukocyte immunoglobulinlike receptor 1 (LIR-1). Although KIRs
recognize specific polymorphisms on the classical HLA-A, -B, and -C
molecules, CD94/NKG2A recognizes nonclassical HLA-E molecules assembled
with a peptide from the leader sequence of HLA-I
molecules.1,2 ILT-2/LIR-1 expressed by NK, T, and myeloid cells recognizes a broad range of cellular HLA-I
molecules3 as well as viral class I-like molecule,
UL-18.4 All these inhibitory receptors have in common one
or more immunoreceptor tyrosine-based inhibition motifs (ITIMs) in
their cytoplasmic tails. On tyrosine phosphorylation, ITIMs recruit
tyrosine phosphatases Src homology 2 domain-containing protein 1 (SHP-1) and/or SHP-2 that can dephosphorylate molecules involved in
immuno-tyrosine-based activation motif (ITAM)-induced signaling
pathways.5,6 KIR2D CD158 receptors possessing 2 immunoglobulin domains are recognized by specific monoclonal antibodies (mAbs) and distinguish HLA-C alleles.7
In the peripheral blood of healthy individuals, low percentages of
KIR+ T cells express a memory CD28 A few studies have reported that CD94 and KIRs are also expressed by
CD8+ T cells infiltrating tumors.14-16 We
previously reported that renal tumors contained particular
CD8+ infiltrating T cells that express an inhibitory NK
receptor from the KIR family (CD158), specific for HLA-C molecules. In
vitro, these KIR+ cytotoxic T lymphocytes (CTLs) correspond
to potential highly lytic effectors, but their functional activity
toward tumor cells is strongly inhibited by the NK
receptor.17 In the present study, a tumor-derived
CD158a+ CTL was stimulated by tumor cells expressing or not
the KIR ligand to investigate the influence of the KIR engagement in
the early biochemical and morphologic events leading to cell
activation. This system constitutes an accurate model to analyze the
interplay between TCR/major histocompatibility complex (MHC)
and KIR/MHC interactions during physiologic CTL/target activation.
The recognition of MHC/peptide complex by TCRs results in the
activation of protein tyrosine kinases (PTKs).18 Among
them, ZAP-70 phosphorylates the adaptor molecule linker for activation of T cells (LAT) that plays a key role in linking TCRs to phospholipase C Culture of tumor cells and CTLs
4D4 CD158+ CTL clone was obtained from direct cloning of
tumor-infiltrating lymphocytes from RCC (patient 7) was
expanded on allogeneic feeder cells in RPMI1640 medium supplemented
with 10% human serum and 30 U/mL interleukin 2 (IL-2; Roussel Uclaff,
Romainville, France). Briefly, 3 × 103 T cells/well
plated with 7 × 104 irradiated allogeneic
peripheral blood mononuclear cells (PBMCs) and 104
irradiated allogeneic lymphoblastoid cell line (LCL; LAZ509) were grown for 14 days. Expression of CD158a by 4D4 CTL was stable over
time in culture.
Cytotoxicity assay
Measurement of intracellular calcium concentration by flow cytometry Target cells were labeled with PKH26 fluorescent cell linker (5.10 6 M dye; Sigma, Saint Quentin, Fallavier,
France), washed 3 times, and rested for 1 hour at 37°C. 4D4
CTL clones (5.106/mL) were labeled with 4 µM Fluo
3-AM (Sigma) for 45 minutes at 37°C, washed twice with
serum rich medium, and resuspended in HEPES
(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid)-buffered medium. Mixed cells (5 × 104 CTLs and
105 target cells/400 µL) were centrifuged 1 minute at
1500 rpm, incubated 1 minute at 37°C, gently resuspended,
and immediately analyzed on Flow cytofluorimeter (FACS-Calibur; Becton
Dickinson, Le Pont de Claix, France). In blocking conditions, target
cells were incubated with saturating concentration of anti-HLA-B/C or
irrelevant anti-HLA-DR mAbs before stimulation. Ca++
release was evaluated by measuring green fluorescence of Fluo3 emission
at 526 nm. The concentration of intracellular calcium was calculated by
using the formula [Ca++]i
nM = Kd (F  Fmin)/(Fmax F) as
previously reported,28 where Kd represents the dissociation constant for
Ca++-bound Fluo-3 and is of 400 nM. Fmax and Fmin were
evaluated by adding a calcium ionophore (ionomycin 10 µg/mL;
Sigma) followed by MnCl2 (2 mM; Sigma) to
Fluo-3-loaded CTLs.
Receptor clustering and raft redistribution by confocal microscopy Lipid raft aggregation on CTLs stimulated by mAb-coated beads has been described.26 Beads (polystyrene latex microspheres; Polysciences) were coated with 10 µg/mL anti-CD3
(UCHT1, IgG1; Becton Dickinson); anti-CD3 + anti-CD158a (10 µg/mL), or anti-HLA-DR (10 µg/mL) and used at 2:1 ratio over T
cells. 4D4 CTL clones labeled with fluorescent B subunit of cholera
toxin (8 µg/mL; Sigma), fluorescein isothiocyanate
(FITC)-CT-B (that binds to GM1 glycosphingolipids in the
lipid rafts) was incubated with mAb-coated beads for 15 minutes at
37°C. T-cell-bead complexes were settled onto poly-l-lysine-coated
slides. After fixation, CTL/beads were saturated with mouse IgG1
antibodies and permeabilized for 10 minutes (HEPES-buffered
phosphate-buffered saline [PBS] containing 3% bovine serum
albumen [BSA] and 0.1% saponin) before staining with anti-Ptyr mAb
(4G10, IgG2b; Euromedex, Souffelweyersheim, France) followed by goat
antimouse IgG2b-Cy5 (Caltag Laboratories, Burlingame, CA).
For CTL/tumor cell interaction analysis, CTLs were mixed to PKH26-labeled tumor cells, centrifuged 2 minutes at 1500 rpm, settled onto slides after gentle resuspension, and incubated at 37°C for 10 minutes. After fixation, CTLs were labeled with anti-Ptyr or anti-CD3 mAb (UCHT1, IgG1) followed by the labeled-isotypic secondary antibodies. Alternatively, CTL/RCC conjugates were stained with Phalloidin Texas-red (Molecular Probes, Eugene OR) to detect polymerized F-actin. The samples were conserved in mounting medium (Vectashield; Biovalley, Conches, France) at +4°C and analyzed by laser scanning confocal microscopy, a Leica TCS Confocal System (Wetzler, Germany). Cells were considered to have clustered receptors if the staining pattern was crescent shaped and if receptors were polarized to one side of the cell.29 A total of 100 conjugates per slide were analyzed to evaluate percentages. Immunoblot and immunoprecipitation analysis 4D4 CTL clones (5 × 105 to 106 per sample for immunoprecipitation and 2 × 105 per sample for whole cell extracts) were stimulated with target cells for 3 minutes at 37°C. CTL stimulations were performed at 7:1 effector-target (E/T) ratio for tumor cells and 5:1 ratio for LCLs. Stimulated cells were rapidly pelleted and lysed for 20 minutes on ice in 1% NP-40 lysis buffer containing 20 mM Tris (tris(hydroxymethyl)aminomethane)-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA (ethyleneglycoltetraacetic acid) and 1% n-Dodecyl beta-D-maltoside in the presence of protease and phosphatase inhibitors: 10 µg/mL leupeptin, 10 mg/mL aprotinin, 1 mM Pefabloc-sc, 50 mM NaF, 10 mM Na4P2O7, and 1 mM NaVO4. Insoluble material was removed by centrifugation for 10 minutes at 14 000 rpm at +4°C. Postnuclear lysate was kept to analyze the protein tyrosine phosphorylated profile, and the remaining material was immunoprecipitated.Cell lysates were subjected to immunoprecipitation for 2 hours with anti-LAT (rabbit antihuman p36 serum directed against 219-233 residues), anti-ZAP-70 (IB60, rabbit polyclonal antibody directed against 266-344 residues) preadsorbed to protein A-Sepharose (O. Acuto, Paris, France), or anti-Vav (mixed H211 and C14 rabbit polyclonal Abs) (Santa Cruz Biotechnology, CA). Immunocomplexes were washed twice in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40 and twice in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl and boiled in sodium dodecyl sulfate (SDS) sample buffer before gel electrophoresis. Whole cell lysates and immunoprecipitated proteins were separated on SDS-polyacrylamide gels and blotted onto nitrocellulose membranes. Separated proteins were probed initially with mAb 4G10 (anti-Ptyr) and after stripping (0.1 M glycine HCL pH 2.3) with specific antibodies: anti-LAT (L. Samelson, National Institutes of Health, Bethesda, MD); anti-ZAP-70 (IB60); anti-Vav-30 mAb (J. Griffin, Boston, MA) and M14, rabbit antihuman SLP-76 (O. Acuto, Paris, France). Proteins were revealed by peroxidase-conjugated goat antimouse or peroxidase-conjugated protein A and developed with the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Orsay, France). Densitometric analysis was performed using Bioprofil Bio 1D Windows application V99.04 (Scanalytics, Fairfax, Vancouver, BC, Canada). Values indicate the ratio of tyrosine phosphorylation to protein signal.
Inhibition of the cytotoxic activity and Ca++ response of CTLs by CD158a NK receptor 4D4 CTL clone expressing a VB13.1 TCR and a unique CD158a receptor (specific for HLA-Cw4 supertype alleles) was derived from tumor-infiltrating lymphocytes of a renal tumor. This tumor contained 2% of CD158a+ CD8+ T cells, and VB13.1+ T cells corresponded to 16% of the CD158a+ T cells (data not shown). This CTL is HLA-A2 restricted and recognized an antigen expressed by tumor cells of different origins (renal, melanoma, breast) as well as normal renal cells and EBV-transformed B cells. To analyze the respective role of TCR/MHC and KIR/MHC engagement on CTL activation, 4D4 CTL clone was stimulated by autologous (RCC-7) renal tumor cells or allogeneic renal tumor cell lines (RCC-6 and RCC-5) displaying different combinations of HLA-A and -C molecules. 4D4 CTL efficiently lysed HLA-A2+ HLA-Cw3 supertype tumor cell line (RCC-6). In contrast, autologous HLA-A2+ HLA-Cw4 cell line (RCC-7) was lysed by 4D4 CTL only when the CD158a/HLA-Cw4 interaction was blocked with anti-HLA-B/C mAb. The HLA-A2 cell line (RCC-5) was not recognized even in
the presence of blocking mAb (Figure 1A,
left panel). EBV-transformed B cells (LCL) derived from the same RCC
patients were lysed with a similar pattern as tumor targets indicating
that 4D4 CTL recognizes a self-antigen (Figure 1A, right panel). In
addition, the lysis of patient 6 cell lines was markedly inhibited in
the presence of anti-CD3 or anti-HLA-A2 mAbs, evidence that the lytic
activity of 4D4 CTL is TCR mediated and restricted by HLA-A2 molecules (data not shown).
The influence of the KIR receptor was assessed on the intracellular calcium [Ca++]i release, one of the earliest events of CTL activation. Figure 1B shows the percentages of T cells releasing intracellular Ca++ following stimulation by LCL. Quantitatively, tumor cells RCC-6 triggered high [Ca++]i release by CTLs (> 600 mM) when compared with stimulation by RCC-7 that engaged KIR and by a nonrelevant target (RCC-5; Figure 1C, left panel). In addition, preincubation of LCL-7 with blocking anti-HLA-B/C mAb restored a considerable [Ca++]i release by CTL comparable to the one detected in response to LCL-6 (Figure 1C, right panel). Thus, the difference of susceptibility of patients 7 and 6 cell lines to specific CTL was exclusively accounted for by CD158a receptor engagement. Lack of lipid rafts polarization on the CD3-activated CTL by CD158a NK receptor Data depicted in Figure 2A indicate that triggering of KIR by specific mAbs dramatically abrogated the CD3-redirected lysis of murine FcR+ P815 cells. Thus, TCRs and KIRs were triggered on CTLs by microbeads coated with anti-CD3
or anti-CD3 + anti-CD158a mAbs, and membrane reorganization was
analyzed with the use of confocal microscopy (Figure 2B). Stimulation
by anti-CD3-coated beads (beads exhibit light red autofluorescence)
induced reorganization of membrane lipid rafts visualized on
FITC-CT-B-labeled CTLs by formation of fluorescent patches and
protrusion of the CTLs at the contact site between cells and beads when
compared with unstimulated CTLs (Figure 2Bi and v). In addition,
labeling with anti-Ptyr mAb revealed a bright polarized red and green
overlapping staining, indicating an increased accumulation of
phosphorylated proteins at the cell/bead contact compared with light
diffuse staining in control cells (Figure 2Bii and vi). Cotriggering of
the TCRs and KIRs on CTLs did not induce redistribution and clustering
of FITC-CT-B-labeled rafts, and staining with anti-Ptyr mAb revealed a
weak and diffuse staining (Figure 2Biii-iv), suggesting that KIR
engagement affects TCR-mediated tyrosine phosphorylation. When CTLs
were stimulated by beads coated with anti-CD3 + anti-HLA-DR,
similar results as those observed with anti-CD3 alone were obtained,
whereas anti-CD158-coated beads had no effect on CTLs (data not
shown). In 3 independent experiments the numbers of CTLs that formed
fluorescent patches at the cell/bead contact were counted and revealed
that the triggering of KIRs markedly decreased the percentages of CTLs aggregating lipid rafts (5% versus 32%). This finding strongly indicates that KIRs play a role in the prevention of lipid raft polarization.
Prevention of lipid raft polarization and CD3 clustering on CTLs by tumor cells cotriggering TCRs and KIRs With the use of fluorescence imaging, we investigated the effect of simultaneous cotriggering of TCR and KIR receptors on the membrane redistribution events at the contact zone between CTL and RCC targets. FITC-CT-B-labeled CTLs were stimulated with RCC-7 or RCC-6 targets and stained with anti-Ptyr mAbs (Ptyr-Cy5, red) after heteroconjugate fixation. Major differences between CTL/RCC-7 and CTL/RCC-6 conjugates were observed at this level of resolution. Figure 3A shows a typical image of interface between CTL and RCC-6 tumor cell with strong lipid raft concentration at the contact zone with the tumor cell that colocalizes in the overlay picture with the dense red anti-Ptyr staining (Figure 3A, upper panels). The lower panels correspond to the contact zone of CTL/RCC-7 conjugates characterized by the absence of accumulation of fluorescent lipid rafts (green) and undetectable level of phosphorylation (Figure 3A, lower panels). Quantitative analysis revealed that only 10% of the CTL/RCC-7 conjugates showed a tight polarization of the fluorescence at contact site, whereas fluorescent patches were evident in 32% of CTL/RCC-6 conjugates. In addition, in Figure 3B double staining with anti-CD3 mAb and anti-Ptyr revealed a zone of dense CD3 staining
at the contact with RCC-6 tumor cells that overlapped with regions of
plasma membrane containing the highest Ptyr accumulation. TCR/CD3
accumulation was observed in aggregated lipid rafts (data not
shown). In CTL/RCC-7 conjugates (Figure 3B, lower panel), anti-CD3
staining displayed a ringlike pattern and was not associated with PTK
activation. These results demonstrate that CD158a engagement by its
specific ligand HLA-Cw4 on RCC-7 markedly impaired lipid raft
coalescence, TCR/CD3 capping, and early TCR signaling through PTK
activation during CTL/tumor cell contact.
Decreased phosphorylation of TCR-induced tyrosine kinase ZAP-70 and LAT on KIR engagement KIRs are rapidly phosphorylated on tyrosine residue of ITIM and recruits phosphatase SHP-1 that is responsible for the KIR inhibitory effect on TCR-mediated signaling.30,31 In the present model, immunoprecipitation of the PTK ZAP-70 showed that a low amount of tyrosine phosphorylation of this PTK was observed following CTL stimulation by RCC and LCL-7 target cells that engage the KIR when compared with stimulation with RCC and LCL-6 cells (Figure 4A, upper panel). Although less obvious, immunoprecipitation of LAT, the ZAP-70 substrate, also showed that KIR engagement by patient 7 cell lines reduced LAT phosphorylation. As indicated by densitometric values, there was a 2.48-fold lower LAT phosphorylation in response to RCC-7 stimulation (Figure 4A, lower panel). In addition, preventing triggering of KIRs during CTL stimulation by masking HLA-C molecules with anti-HLA-B/C mAb (Figure 4B, lane 3) on RCC-7 targets cells resulted in a markedly restored phosphorylation on tyrosine residues of ZAP-70 and LAT proteins. These results provide evidence that KIR triggering decreases early TCR-mediated signaling in the tumor-specific 4D4 CTL clone.
Failure of TCR-induced Vav phosphorylation and actin cytoskeleton redistribution on KIR ligation Protein tyrosine phosphorylation patterns of 4D4 CTL clone after stimulation by the previous RCC targets revealed marked differences in CTLs stimulated with targets expressing the KIR ligand (RCC-7, Figure 5, lane 2) compared with the stimulation with targets engaging TCR only (RCC-6, lane 3). Compared with unstimulated CTLs (lane 1) and to background tyrosine phosphorylated proteins in RCC-7 and RCC-6 tumor cells (lanes 4 and 5), stimulation of CTLs with the susceptible RCC-6 targets (lane 3) resulted in phosphorylation of proteins around 95 kDa and 76 kDa, respectively, that were not detected in CTLs stimulated by RCC-7 (lane 2). Immunoblotting with specific antibodies indicated that these proteins presumably corresponded to Vav and SLP-76 proteins, respectively (Figure 5). Indeed, immunoprecipitation of Vav shows that triggering of KIRs by RCC-7 targets totally prevents Vav phosphorylation compared with RCC-6 targets that do not engage the KIRs (Figure 5B, lanes 2 and 5). Interestingly, preventing KIR triggering by specific mAbs on RCC-7 tumor cells restored the tyrosine phosphorylation of Vav (Figure 5 B, lane 3). In addition, confocal microscopy analyses further indicate that actin cytoskeleton rearrangement in CTLs was greatly affected by KIR engagement. Figure 5C shows that in CTL/RCC-6 conjugates, polymerized F-actin (red staining) was accumulated at the same zone that polarized lipid rafts (green) (Figure 5C, upper panels). In contrast, a homogeneous distribution of membrane rafts and no marked actin polymerization were observed in CTLs stimulated by RCC-7 targets (Figure 5C, lower panels).
RCC is considered as potentially immunogeneic tumors on the basis of the rare but documented spontaneous regressions reported and in light of the clinical responses obtained in some patients treated with cytokines. Although RCC is infiltrated by numerous T cells, confirming that the immune system may control the growth of these tumors, this tumor model is also characterized by the existence of various immune defects that result in the global functional alteration of the cytotoxic T-effector cells.32-34 It is known that human solid tumors mostly express tissue-specific antigens or self-antigens that may induce local tolerance, and cytotoxic T cells infiltrating RCC may correspond to antigen-experienced CTLs. In accordance with this hypothesis, we have previously shown that clonal KIR+ CTLs, bearing a memory-activated phenotype, infiltrated RCC.17 These KIR+ CTLs that recognize tissue-specific antigens and/or self-antigens represent potentially lytic T cells, but their activity against tumor targets is inhibited by the KIRs.17,35 In the present study, we took advantage of a tumor-derived 4D4 CTL clone, expressing a unique CD158a receptor (specific for HLA-Cw4 supertype) that recognizes an HLA-A2-restricted self-antigen, to determine the influence of such receptor on the early and late steps of CTL activation. The CTL clone 4D4 efficiently lysed allogeneic HLA-A2+, Cw3+ patient 6 targets, whereas lysis and intracellular Ca++ mobilization toward autologous HLA-A2+, Cw4+ patient 7 targets were abrogated following specific CD158a triggering. It is established that KIR receptors counteract the signaling initiated by the TCR/CD3 receptor in CTLs, and the underlining mechanism involves, at least in part, the recruitment of SHP-1 following phosphorylation of the KIR ITIMs by Src family kinases. SHP-1 extinguishes signaling on neighboring ITAMs and efficiently inhibits CD3 phosphorylation,30 suggesting a sequential aspect in the response to TCR and KIR coengagement. Our data show that when the 4D4 CTL clone was stimulated by antigen-positive targets lacking the KIR ligand (patient 6 targets), ZAP-70 and its substrate LAT, 2 proteins known to be essential for the propagation of TCR-mediated signal, were tyrosine phosphorylated.19 In contrast, after 4D4 CTL stimulation by patient 7 cells that trigger the CD158a receptor, we observed a reduced level of ZAP-70 and LAT phosphorylation. As shown for cytotoxicity and calcium response, preventing triggering of KIRs by masking of HLA-C molecules on patient 7 targets restored the phosphorylation of these 2 essential signaling proteins, indicating that KIRs efficiently down-regulated initial TCR-mediated signaling. Analysis of morphologic events by confocal microscopy studies indicate that TCR-induced signaling takes place in the membrane rafts and further illustrate that TCR and CD158 coengagement abrogates TCR/CD3 and Ptyr accumulation at the CTL/target contact zone. Following CTL/target-specific conjugate, phosphorylation of KIRs on CTL 4D4 recruits SHP-1 (data not shown) may inhibit the signaling by the few TCRs engaged. On the basis of these results, we may assume that TCRs and KIRs act concomitantly with early signaling of TCRs, involving the rapid phosphorylation of ITIM on KIRs and further down-regulation of TCR signaling. Data on early clustering of the TCR complex,36 as well as on the binding kinetics and spatial position of KIRs,37 emphasize the inhibitory role of KIRs on the early consequences of TCR engagement with its MHC/peptide ligand interrupting the activation program. It is clearly established that LAT, predominantly localized into lipid
rafts, plays a central role in signal transduction on TCR engagement.
Indeed, TCR-mediated tyrosine phosphorylation of LAT results in the
formation of a structural scaffold of downstream signaling proteins
such as Vav, PLC The dynamic reorganization of membrane proteins, also termed immunologic synapse, is initiated by coalescence of lipid rafts and correlates with the sustained activation of T cells.43,44 In cytotoxic T-cell effectors, the immunologic synapse brings the T-cell secretory apparatus into close contact with the target for a polarized release of cytokines and cytotoxic mediators.45,46 Our data show that KIR engagement by targets was effective in inhibiting TCR-mediated lipid raft coalescence, TCR/CD3 and phosphotyrosine protein accumulation at the contact site, as the underlining mechanism for abrogation of CTL-mediated killing. Our findings are supported by a recent report of Dietrich et al47 outlining the existence of a cross talk between ILT-2 and TCRs with a reduction of both TCR signaling and TCR-induced reorganization of the actin cytoskeleton at the interface of the APC-T cell after ILT-2 ligation.47 Taken together, the present studies emphasize that, although
KIR+ CTL effectively recognized renal tumor cells, KIR
engagement induced an alteration of early TCR/CD3 signaling and
prevented the membrane raft reorganization, resulting in target
protection from lysis. KIRs have been proposed as a regulator of
homeostasis of memory T-cell subsets, involved in their in vivo
survival.11 In the context of an immune response to tumor,
KIRs may be involved in the local functional alteration of
self-specific CTLs. In renal tumors, KIR+ CTL reflect the
presence of an ongoing antitumor immune response of memory T cells
induced in response to chronic antigen stimulation by tumor cells.
Although the mechanisms controlling the induction of such inhibitory
receptors on CTLs are not known, their influence on tumor-specific CTL
functions is remarkable, and the expression of KIRs by TILs represent a
powerful mechanism that contributes to antigen-specific
CD8+ dysfunction. In that context, an in vivo up-regulation
of CD94
We thank Dr Frédéric Triebel for providing CTL clones, Prof Alessandro Moretta for helpful discussions and for the kind gift of anti-KIR mAbs, Yann Lécluse for flow cytometry analysis, and Dr Salvatore Valitutti for technical advice on confocal analysis and for helpful discussions.
Submitted March 11, 2002; accepted May 6, 2002.
Prepublished online as Blood First Edition Paper, June 21, 2002; DOI 10.1182/blood-2002-02-0643.
Supported by grants from INSERM, the Association pour la Recherche sur le Cancer (grants 2038 and 5253) (N.G. and A.G.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anne Caignard, INSERM 487, Institut Gustave Roussy, PR1, 39, rue Camille Desmoulins, 94805 Villejuif Cedex 94, France; e-mail: caignard{at}igr.fr.
1. Lanier L. NK cell receptors. Ann Rev Immunol. 1998;16:359-393[CrossRef][Medline] [Order article via Infotrieve]. 2. Braud VM, Allan DS, Callaghan AO, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-795[CrossRef][Medline] [Order article via Infotrieve].
3.
Colonna M, Navarro F, Bellon T, et al.
A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.
J Exp Med.
1997;186:1809-1818 4. Cosman DN, Franger L, Borges M, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7:273-282[CrossRef][Medline] [Order article via Infotrieve]. 5. Binstadt BA, Brumbaugh KM, Dick CJ, et al. Sequential involvement of Lck and SHP-1 with MHC recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity. 1996;5:629-638[CrossRef][Medline] [Order article via Infotrieve]. 6. Long EO. Regulation of immune responses by inhibitory receptors. Adv Exp Med Biol. 1998;452:19-28[Medline] [Order article via Infotrieve].
7.
Vitale M, Sivori S, Pende D, et al.
Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones.
Proc Natl Acad Sci U S A.
1996;93:1453-1457 8. Ferrini S, Cambiaggi A, Meazza R, et al. T cell clones expressing the natural killer cell related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur J Immunol. 1994;24:2294-2298[Medline] [Order article via Infotrieve].
9.
Mingari MC, Schiavetti F, Ponte M, et al.
Human CD8+T lymphocyte subsets that express HLA class I specific inhibitory receptors represent oligoclonally or monoclonally expanded populations.
Proc Natl Acad Sci U S A.
1996;93:12433-12438
10.
Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P.
Differential expression of leukocyte receptor complex Ig like receptors correlates with the transition from effector to memory.
J Immunol.
2001;166:3933-3941 11. Ugolini S, Arpin C, Anfossi N, et al. Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol. 2001;2:430-435[Medline] [Order article via Infotrieve].
12.
Phillips JH, Gumperz JE, Parham P, Lanier LL.
Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes.
Science.
1995;268:403-405 13. Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum Immunol. 2000;61:44-50[CrossRef][Medline] [Order article via Infotrieve]. 14. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199-208[CrossRef][Medline] [Order article via Infotrieve].
15.
Bakker AB, Phillips JH, Figdor CG, Lanier LL.
Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells and antigen-specific CTL.
J Immunol.
1998;160:5239-5245 16. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T cell responses. Immunol Today. 1998;19:153-157[CrossRef][Medline] [Order article via Infotrieve].
17.
Guerra N, Guillard M, Angevin E, et al.
Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor specific T lymphocytes infiltrating renal cell carcinoma.
Blood.
2000;95:2883-2889 18. Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol. 1997;9:205-212[CrossRef][Medline] [Order article via Infotrieve]. 19. Finco TS, Kadlecek T, Zhang W, Samelson LE, Weiss A. LAT is required for TCR-mediated activation of PLCgamma1 and the Ras pathway. Immunity. 1998;9:617-626[CrossRef][Medline] [Order article via Infotrieve]. 20. Bunnell SC, Kapoor V, Trible RP, Zhang W, Samelson LE. Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. Immunity. 2001;14:315-329[CrossRef][Medline] [Order article via Infotrieve]. 21. Fisher KD, Kong YY, Nishina H, et al. Vav is a regulator of cytoskeletal reorganization mediated by the T cell receptor. Curr Biol. 1998;8:554-558[CrossRef][Medline] [Order article via Infotrieve]. 22. Holsinger LJ, Graef IA, Swat W, et al. Defects in actin-cap formation in vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr Biol. 1998;8:563-572[CrossRef][Medline] [Order article via Infotrieve].
23.
Krause M, Sechi AS, Konradt M, Monner D, Gertler FB, Wehland J.
Fyn binding protein (Fyb)/SLP-76-assocaited protein (SLAP), Ena/vasodilatator-stimulted phosphoprotein(VASP) proteins and the Arp2/3 complex link T cell receptor (TCR) to the actin cytoskeleton.
J Cell Biol.
2000;149:181-194 24. Xavier R, Bennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity. 1998;8:723-733[CrossRef][Medline] [Order article via Infotrieve].
25.
Janes P, Ley S, Magee A.
Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor.
J Cell Biol.
1999;147:447-461
26.
Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A.
T lymphocyte costimulation mediated by reorganization of membrane microdomains.
Science.
1999;283:680-682
27.
Speiser DE, Pittet MJ, Valmori D, et al.
In vivo expression of natural killer cell inhibitory receptors by human melanoma specific cytolytic T lymphocytes.
J Exp Med.
1999;190:775-782
28.
Grynkiewicz G, Poenie M, Tsien RY.
A new generation of Ca2+ indicators with greatly improved fluorescence properties.
J Biol Chem.
1985;260:3440-3450 29. Leupin O, Zaru R, Laroche T, Muller S, Valitutti S. Exclusion of CD45 from the T cell receptor signaling area in antigen stimulated T lymphocytes. Curr Biol. 2000;10:277-280[CrossRef][Medline] [Order article via Infotrieve]. 30. Bléry M, Olcese L, Vivier E. Early signaling via inhibitory and activating NK receptors. Hum Immunol. 2000;61:51-64[CrossRef][Medline] [Order article via Infotrieve].
31.
Su MW, Yu CL, Burakoff SJ, Jin YJ.
Targeting Src homology 2 domain-containing tyrosine phosphatase (SHP-1) into lipid rafts inhibits CD3 induced T cell activation.
J Immunol.
2001;166:3975-3982 32. Bichler KH, Kleinknecht S, Strohmaier WL. Immune status and immune therapy of renal cell carcinoma. Urol Int. 1990;45:269-283[Medline] [Order article via Infotrieve].
33.
Finke JH, Zea AH, Stanley J, et al.
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Cancer Res.
1993;53:5613-5616 34. Kolenko V, Wang Q, Riedy MC, et al. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 and IL-2 receptor signaling: role of soluble products from renal cell carcinomas. J Immunol. 1997;159:3057-3067[Abstract].
35.
Gati A, Guerra N, Giron-Michel J, et al.
Tumor cells regulate the lytic activity of tumor-specific cytotoxic T lymphocytes by modulating the inhibitory natural killer receptor function.
Cancer Res.
2001;61:3240-3244 36. Fahmy T, Bieler J, Edidin M, Schneck J. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity. 2001;14:135-143[Medline] [Order article via Infotrieve]. 37. Vales-Gomez M, Reyburn H, Mandelboim M, Strominger J. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity. 1998;9:337-344[CrossRef][Medline] [Order article via Infotrieve]. 38. Zhang W, Sloan-Lancaster J, Kitchen J, Trible R, Samelson L. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 1998;92:83-92[CrossRef][Medline] [Order article via Infotrieve].
39.
Harder T, Kuhn M.
Selective accumulation of raft-associated membrane protein LAT in T cell receptor signaling assemblies.
J Cell Biol.
2000;151:199-207
40.
Wulfing C, Davis MM.
A receptor/cytoskeletal movement triggered by costimulation during T cell activation.
Science.
1998;282:2266-2269 41. Crespo P, Schuebel K, Ostrom A, Gutkind J, Bustelo X. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature. 1997;385:169-172[CrossRef][Medline] [Order article via Infotrieve].
42.
Villalba M, Bi K, Rodriguez F, Tanaka Y, Schoenberger S, Altman A.
Vav1/Rac-dependent actin cytoskeleton reorganization is required for lipid rafts clustering in T cells.
J Cell Biol.
2001;155:331-338 43. Lanzavecchia A, Sallusto F. From synapses to immunological memory: the role of sustained T cell stimulation. Curr Opin Immunol. 2000;12:92-98[CrossRef][Medline] [Order article via Infotrieve]. 44. Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. Annu Rev Immunol. 2001;19:375-396[CrossRef][Medline] [Order article via Infotrieve].
45.
Kupfer A, Singer SL, Dennert G.
On the mechanism of unidirectional killing in mixtures of two cytotoxic T lymphocytes. Unidirectional polarization of cytoplasmic organelles and the membrane-associated cytoskeleton in the effector cell.
J Exp Med.
1986;163:489-498 46. Stinchcombe J, Bossi G, Booth S, Griffiths G. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001;15:751-761[CrossRef][Medline] [Order article via Infotrieve].
47.
Dietrich J, Cella L, Colonna M.
Ig-like transcript 2 (ILT-2)/leukocyte ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization.
J Immunol.
2001;166:2514-2521 48. Moser J, Gibbs J, Jensen P, Lukacher A. CD94-NKG2A receptors regulate antiviral CD8+ T cell responses. Nat Immunol. 2002;3:189-195[CrossRef][Medline] [Order article via Infotrieve].
49.
Childs R, Chernoff A, Cententin N, et al.
Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cells transplantation.
N Engl J Med.
2000;343:750-758 50. Childs R, Drachenberg D. Allogeneic stem cell transplantation for renal cell carcinoma. Curr Opin Urol. 2001;11:495-502[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. T. van der Veken, M. Diez Campelo, M. A. W. G. van der Hoorn, R. S. Hagedoorn, H. M. E. van Egmond, J. van Bergen, R. Willemze, J. H. F. Falkenburg, and M. H. M. Heemskerk Functional Analysis of Killer Ig-Like Receptor-Expressing Cytomegalovirus-Specific CD8+ T Cells J. Immunol., January 1, 2009; 182(1): 92 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Alter, S. Rihn, H. Streeck, N. Teigen, A. Piechocka-Trocha, K. Moss, K. Cohen, A. Meier, F. Pereyra, B. Walker, et al. Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8+ T Cells in Human Immunodeficiency Virus Type 1 Infection J. Virol., October 1, 2008; 82(19): 9668 - 9677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fourmentraux-Neves, A. Jalil, S. Da Rocha, C. Pichon, S. Chouaib, G. Bismuth, and A. Caignard Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells Blood, September 15, 2008; 112(6): 2381 - 2389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Iliopoulou, M. V. Karamouzis, I. Missitzis, A. Ardavanis, N. N. Sotiriadou, C. N. Baxevanis, G. Rigatos, M. Papamichail, and S. A. Perez Increased Frequency of CD4+ Cells Expressing CD161 in Cancer Patients Clin. Cancer Res., December 1, 2006; 12(23): 6901 - 6909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Campillo, J. A. Martinez-Escribano, M. R. Moya-Quiles, L. A. Marin, M. Muro, N. Guerra, A. Parrado, M. Campos, J. F. Frias, A. Minguela, et al. Natural Killer Receptors on CD8 T Cells and Natural Killer Cells from Different HLA-C Phenotypes in Melanoma Patients. Clin. Cancer Res., August 15, 2006; 12(16): 4822 - 4831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Henel, K. Singh, D. Cui, S. Pryshchep, W.-W. Lee, C. M. Weyand, and J. J. Goronzy Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors Blood, June 1, 2006; 107(11): 4449 - 4457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dorothee, I. Vergnon, F. El Hage, B. L. M. Chansac, V. Ferrand, Y. Lecluse, P. Opolon, S. Chouaib, G. Bismuth, and F. Mami-Chouaib In Situ Sensory Adaptation of Tumor-Infiltrating T Lymphocytes to Peptide-MHC Levels Elicits Strong Antitumor Reactivity J. Immunol., June 1, 2005; 174(11): 6888 - 6897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gati, N. Guerra, C. Gaudin, S. Da Rocha, B. Escudier, Y. Lecluse, A. Bettaieb, S. Chouaib, and A. Caignard CD158 Receptor Controls Cytotoxic T-Lymphocyte Susceptibility to Tumor-Mediated Activation-Induced Cell Death by Interfering with Fas Signaling Cancer Res., November 1, 2003; 63(21): 7475 - 7482. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
1 and Ras pathways.
chain and TCR/CD3 capping.